Close Menu

NEW YORK (GenomeWeb) — Luminex reported after the close of the market Monday a 12 percent spike in third quarter revenues driven primarily by growth in assay sales across all major product categories.

The company also pushed back the commercialization timeline for Aries, its sample-to-answer molecular diagnostics system.

For the three months ended Sept. 30, the Austin, Texas-based molecular diagnostics firm tallied $56.7 million in revenues, compared to $50.8 million in the year-ago period, and edging the average analyst estimate of $56.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new study catalogues the genome and evolutionary history of the oak family, UPI reports.

Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.

A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.

In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.

Oct
21
Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.